Table I.
Patient characteristics for the platinum-sensitive and platinum-resistant groups.
| Variable | Platinum-sensitive group | Platinum-resistant group | P-value |
|---|---|---|---|
| No. of cases | 26 | 25 | |
| Age, years (mean ± SD) | 60.4±11.7 | 58.5±8.6 | 0.521a |
| FIGO stage, n | 0.418b | ||
| IIIA | 1 | 0 | |
| IIIB | 3 | 1 | |
| IIIC | 20 | 18 | |
| IVA | 1 | 3 | |
| IVB | 1 | 3 | |
| Tumor marker CA125, U/ml (mean) | 3,467.6 | 2,057.4 | 0.309a |
| Postoperative residual disease, n | 0.005b | ||
| None | 5 | 0 | |
| ≤1 cm | 8 | 2 | |
| >1 cm | 13 | 23 |
a
Student's t-test
b
Fisher's exact test. CA125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics.